Awaiting development: Guidance and quality standards

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 11 selected

Guidance programme

Showing 1 to 25 of 299

TitleType
Abatacept for treating active idiopathic inflammatory myopathies [TSID10095]Technology appraisal guidance
Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389]Technology appraisal guidance
Acalabrutinib with R-CHOP for untreated non-germinal centre B-cell diffuse large B-cell lymphoma [ID6614]Technology appraisal guidance
Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]Technology appraisal guidance
Adagrasib with cetuximab for treating KRAS G12C mutation-positive advanced colorectal cancer after 1 treatment line [TSID12305]Technology appraisal guidance
Adalimumab for treating early Dupuytren's contracture [ID6276]Technology appraisal guidance
Afamitresgene autoleucel for previously treated MAGE-A4 positive advanced synovial sarcoma or myxoid round cell liposarcoma [ID4064]Technology appraisal guidance
Aficamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy [ID6668]Technology appraisal guidance
Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]Technology appraisal guidance
Alpha-1 antitrypsin for treating high-risk acute graft-versus-host disease after a haematopoietic stem cell transplant in people 12 years and over [TSID12036]Technology appraisal guidance
Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer [ID6471]Technology appraisal guidance
Aprocitentan for treating resistant hypertension [TSID10395]Technology appraisal guidance
Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasiaMedical technologies guidance
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894]Technology appraisal guidance
Atezolizumab with chemotherapy for adjuvant treatment of stage 3 colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID6646]Technology appraisal guidance
Atrasentan for treating primary IgA nephropathy [ID6558]Technology appraisal guidance
Avexitide for treating hypoglycaemia after bariatric surgery [ID6725]Technology appraisal guidance
Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]Technology appraisal guidance
Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]Technology appraisal guidance
Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [ID6541]Technology appraisal guidance
Belzutifan for treating advanced pheochromocytoma or paraganglioma [TSID12304]Technology appraisal guidance
Belzutifan with pembrolizumab and lenvatinib for untreated advanced clear cell renal cell carcinoma [ID6605]Technology appraisal guidance
Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer [TSID11769]Technology appraisal guidance
Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]Technology appraisal guidance
Bentracimab for reversing the antiplatelet activity of ticagrelor [TSID10550][ID6344]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All